Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lafutidine vs Famotidine vs Omeprazole in Erosive Esophagitis
NCT01499368Phase 3Completed
- Sponsor
- Boryung
- Start
- Nov 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lafutidine in erosive esophagitis (EE) (3 arms), sponsored by Boryung. Primary endpoint: Recovery Rates of Reflux Esophagitis at 8 weeks. Started Nov 2011; status: completed.
02
Drugs
lafutidine
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT01499368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499368.